Dear Dr. Smith:


We acknowledge receipt of your submission dated May 9, 2003.

Your submission of May 9, 2003, constituted a complete response to our April 23, 2003, action letter.

This supplemental new drug application provides for revisions to the WARNINGS section of the Lovenox package insert (PI) regarding mechanical prosthetic heart valves.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions listed below.

1. In the WARNINGS section, ninth paragraph, sixth sentence that begins “Women with mechanical prosthetic heart valves . . .” the term “still birth” should be presented as one word “stillbirth” so that the sentence reads “Women with mechanical prosthetic heart valves may be at higher risk for thromboembolism during pregnancy, and, when pregnant, have a higher rate of fetal loss from stillbirth, spontaneous abortion and premature delivery.”

2. In the HOW SUPPLIED section, in the third paragraph, delete the redundant period at the end of the first sentence that reads “1. 100 mg/mL Concentration: 30 mg/0.3 mL ampules, 30 mg/0.3 ml and 40 mg/0.4 mL prefilled single-dose syringes, 60 mg/0.6 mL, 80 mg/0.8 ml, and 100 mg/1 ml prefilled, graduated, single-dose syringes, 300 mg/3.0 ml multiple-dose vials..”

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the submitted labeling (package insert submitted May 9, 2003). These revisions are terms of the approval of this application.
Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-164/S-050.” Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Diane Moore, Regulatory Project Manager, at (301) 827-7476.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.
Director
Division of Gastrointestinal & Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Joyce Korvick
7/1/03 12:45:53 PM
for Dr. Robert Justice